SRC and ovarian neoplasm: Taken together, our data suggest that specifically suppressing ANGPTL4 in ovarian tumors decreases vascular angiogenesis through dissociation of the VEGFR2/VE-cadherin/Src complex and phosphorylation of VEGFR2 at Y949 and therefore inhibits tumor growth and metastasis.